e2814
mAbexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Dec 16, 2019 (NCT04231513)
Timeline
Indications
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
MAPT inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06602258 | Phase 2 | Sep 30, 2024 | Eisai |
| NCT05269394 | Phase 2/Phase 3 (Phase 3) | Dec 22, 2021 | Accelerating Medicines Partnership, Alzheimer's Association, Eisai, National Institute on Aging (NIA), Washington University in St. Louis |
| NCT04971733 | Phase 1/Phase 2 (Phase 2) | Jun 28, 2021 | Eisai |
| NCT04231513 | Phase 1 | Dec 16, 2019 | Eisai |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 4 | 3 | 3 | 2019 |
| Accelerating Medicines Partnership | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Alzheimer's Association | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2021 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1